Eli Lilly markets Humapen Ergo II in Bangladesh
Monday, 21 December 2009
Eli Lilly & Company, a world leading pharmaceutical company, last week marketed its world class insulin device Humapen Ergo II in Bangladesh, a press release said.
Swapan Kumar Modak, managing director of International Agencies Bangladesh Limited, the local partner of Eli Lilly, said "We have marketed our Humapen Ergo II in Bangladesh diabetes market that will break the monopoly business and will provide better service and option of treatment to the diabetic patients".
He also said that this newly-introduced devices would be easy and comfortable. Shehryar Ansari, managing director of Eli Lilly Pakistan (Private) Limited presented the superiority and benefit of using Humapen Ergo II and also mentioned its strong commitment to diabetes care in Bangladesh.
The programme was chaired by Hajera Mahtab. AK Azad Khan was the chief guest in the programme. Among others, Director General of BIRDEM Ziauddin Ahmed and doctors were present in the launching programme.
Swapan Kumar Modak, managing director of International Agencies Bangladesh Limited, the local partner of Eli Lilly, said "We have marketed our Humapen Ergo II in Bangladesh diabetes market that will break the monopoly business and will provide better service and option of treatment to the diabetic patients".
He also said that this newly-introduced devices would be easy and comfortable. Shehryar Ansari, managing director of Eli Lilly Pakistan (Private) Limited presented the superiority and benefit of using Humapen Ergo II and also mentioned its strong commitment to diabetes care in Bangladesh.
The programme was chaired by Hajera Mahtab. AK Azad Khan was the chief guest in the programme. Among others, Director General of BIRDEM Ziauddin Ahmed and doctors were present in the launching programme.